Japan, U.S. Stay Aligned on Yen as Currency Surges 
Iran Plans New Gulf Restricted Zone as Hormuz Tensions Push Oil Higher 
Japan GDP Growth Beats Forecast, Boosting BOJ Rate Hike Bets 
Yen Rebounds as BOJ Rate Hike Bets Rise 
Jefferies Names 6 Top India Stock Picks Across Key Sectors 
Uranium Prices Could Top $100 as Nuclear Demand Grows 
US Stock Futures Mixed as Strong Jobs Data Boosts Fed Rate Hike Bets 
Oil Prices Climb as Iran Threatens Gulf Energy Infrastructure 
Asian Currencies Mixed as Yen Rallies on BOJ Bets 
China Expands Influence in Global Gold Market 
Oil Prices Rise as Hormuz Tensions Threaten Supply 
China Exports Surge 25% in August as Trade Surplus Hits $119 Billion 
ECB Set for September Rate Hike as Energy Prices Fuel Inflation 
Hungary Industrial Output Beats Forecasts With 4.7% July Growth 
OPEC+ Expected to Hold October Oil Output Steady 
Asian Stocks Rally as AI Optimism Fuels Chipmaker Surge 
Add as a preferred source on Google
European stock markets traded mixed on Monday as renewed uncertainty over U.S. trade tariffs dampened investor sentiment, while Novo Nordisk shares plunged following disappointing obesity drug trial results. Germany’s DAX fell 0.5% to lead regional losses, the UK’s FTSE 100 edged down 0.1%, and France’s CAC 40 managed a modest 0.1% gain in early trading.
Global equities initially rallied after the U.S. Supreme Court invalidated most of former President Donald Trump’s previously imposed tariffs, ruling that the emergency law used did not authorize such measures. However, Trump quickly introduced a new global tariff plan over the weekend, announcing levies of 10% to 15% that could remain in place for up to five months. The sudden policy shift reignited concerns about trade stability and weighed on overall risk appetite. European Central Bank President Christine Lagarde emphasized the importance of predictable trade rules, noting that uncertainty can disrupt global investment and economic equilibrium.
Recent economic data had supported optimism across Europe. The STOXX 600 index reached record highs last week as Eurozone business activity accelerated faster than expected. Manufacturing returned to growth territory for the first time since October, and Germany’s Ifo business climate index climbed to 88.6 in February, signaling early signs of economic recovery in Europe’s largest economy.
In corporate news, Novo Nordisk stock dropped more than 10% after its experimental obesity treatment CagriSema failed to meet a primary endpoint in a head-to-head trial against Eli Lilly’s Tirzepatide. The setback intensifies competition in the rapidly expanding weight-loss drug market, where Novo’s Wegovy and Ozempic previously dominated.
Meanwhile, oil prices retreated ahead of a third round of U.S.-Iran nuclear talks in Geneva. Brent crude slipped to $70.96 per barrel, while West Texas Intermediate fell to $66.15, as hopes for a diplomatic breakthrough eased supply disruption concerns.
